The US compute licensing rule takes effect Nov. 19 as Beijing warns of countermeasures and Trump meets Xi in Shenzhen.
Bausch + Lomb Is Beating Estimates by 62%. The Stock Barely Moved.
BLCO's earnings are growing nearly three times faster than revenue, yet the market still prices it like a turnaround story…
Europe Is Tightening Rules on Chinese Rail and Grid Bids. Siemens and Nexans Stand to Gain.
Brussels’ procurement overhaul is now in the legislative process, and the best-positioned firms are ones many investors have overlooked.
Micron Made $133 Billion Last Year. Its P/E Is Below 5.
Six record quarters, HBM4 shipping, and a sub-5 forward P/E.
AppLovin Is 44% Off Its High. The E-Commerce Bet Is Next.
A 55% revenue quarter, an 84% EBITDA margin, and an e-commerce push just beginning.
ACA Premiums Are Up 58%. What to Do Before Jan. 15
Open enrollment is live. The deadlines matter, and so do Centene, HCA, and 11 states offering help.
Alibaba Earnings Loom. The Stock Has Been Punished.
BABA reports Thu, Nov. 19 with EPS expected to jump year over year, but a 7% selloff shows export-control fear…
FAA Router Failure Left 4,700 Flights Cancelled. Here Is Who Cleans Up the Mess.
Airlines open Monday still unwinding a historic ground stop, while defence contractors tied to the modernisation push face a fresh…
China’s Consumers Aren’t Spending. What That Means for Your Portfolio.
With retail sales barely above zero and EV volumes falling for a tenth straight month, investors need to ask how…
Moderna’s $4.5B Annual Cost Run Rate Is the Real Story
Better revenue growth and a cancer vaccine win cannot hide that Moderna’s path to profitability just got longer.
